Last update Jan. 19, 2023
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
ベンドロフルメチアジド is Bendroflumethiazide in Japanese.
Is written in other languages:ベンドロフルメチアジド is also known as
Main tradenames from several countries containing ベンドロフルメチアジド in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 100 | % |
Molecular weight | 421 | daltons |
Protein Binding | 96 | % |
VD | 1.48 | l/Kg |
pKa | 9.04 | - |
Tmax | 2 | hours |
T½ | 3 - 4 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It is used for hypertension, edema, associated with heart failure, and kidney or liver disorders. It has been used for suppression of the onset of lactation (De Gezelle 1979). Oral administration once a day.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (very high percentage of protein binding, moderately high molecular weight and very wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.
Long-term treatment with diuretic drugs (particularly those Thiazides with long lasting effect and loop-acting drugs) may inhibit lactation. Use a lower dose as possible, especially during the first postnatal month.
Expert authors consider the use of Bendroflumethiazide to be safe during breastfeeding. (Kearney 2018)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.